knowledge -WSS

knowledge

author：focus 2025-09-28 00:52:09 - browse：57

Axovant Sciences(AXON) is the main event in biotech’s September cavalcade of clinical trial readouts, but while we wait, it’s a good idea to prep for important — and stock-moving — data releases from Zogenix(ZGNX) and Amicus Therapeutics(FOLD).

Zogenix’s lead drug, called ZX008, is a low-dose liquid formulation of the old serotonin booster fenfluramine. The company is developing ZX008 to treat children with Dravet syndrome, a rare and severe type of epilepsy.

You might remember fenfluramine as part of the “fen-phen” obesity regimen that was pulled from the market in 1997 because fenfluramine (at a higher dose) caused severe damage to people’s heart valves.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Drug repurposing or repositioning? The language matters
Next article： Why the Crimean Bridge is key to Russia's war in Ukraine

WSS

Merus drug and Keytruda shrank tumors in patients with head and neck cancer

Stanford president to resign after investigation of research

Gilgo Beach murders: What questions remain following Rex Heuermann's arrest?

Ebola public health emergency is over, WHO declares

Seattle police shoot person suspected in downtown stabbing

Do more moles mean more problems? Not so, says new study

entertainment

knowledge

hotspot

Duchenne breakthrough therapy leaves behind pioneering families

Couple fighting to bring baby home from Mexico are finally reunited

Medical leaders decry Supreme Court decision on affirmative action

Russia strikes Ukraine's critical port facilities in Odesa after halting grain deal

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Gene therapies for deafness raise the question: Do deaf people want a 'cure'?

Heart attack and stroke risk calculators need revising

STAT's 2023 biotech VC rankings: ARCH Venture Partners tops list

23andMe had bad news about my health. I wish a person had delivered it

How dance can help health care workers heal from trauma

explore

Startling documents reveal new facets of Sacklers' opioid empire

Childbirth

Researchers separate signal from noise in heart wearable data

Health insurers say they are turning to AI to cut costs, improve care

Readout Newsletter: Moderna bird flu vaccine, Biohaven, ASCO

No Labels group has 'steep climb,' but third party 'worth trying': Larry Hogan

explore

hotspot

entertainment

entertainment